Eye health and ophthalmology companies develop diagnostics, treatments and research technologies for conditions affecting vision and the structures of the eye. Their work supports earlier disease detection, improved patient monitoring and the development of new ocular therapies.
This category includes companies working on:
Browse 26 UK eye health and ophthalmology companies below.
Gene therapy company targeting complement-mediated ocular diseases
Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies and protein-based therapeutics for diseases driven by dysregulation of the complement immune pathway. A spin-out from the University of Manchester, the company's lead programme CTx001 is an AAV-based gene therapy for geographic…
AAV gene therapy for Bardet-Biedl syndrome and genetic obesity
Axovia Therapeutics is a biotechnology company developing adeno-associated viral gene therapies for inherited ciliopathies and genetic obesity. Its lead candidate delivers a functional BBS1 gene into retinal cells to investigate treatment of vision loss associated with Bardet-Biedl syndrome. A first-in-human, early…
Antibody inhibitors of metzincin proteases for eye disease and cancer
Vasgen develops antibody therapeutics for eye disease and cancer, focusing on enzymes known as metzincin proteases. Its discovery platform uses monoclonal antibodies to inhibit these enzymes selectively, offering a different approach to targets that have proved challenging for conventional small-molecule medicines.…
Specialist preclinical CRO for ophthalmic retinal disease drug development
MediNect Ophtho is a contract research organisation providing specialist preclinical services for ophthalmic drug development, with an exclusive focus on retinal disease. Operating from Belfast, the company offers in vivo and ex vivo retinal disease models, proof-of-concept studies, DMPK and ADME studies, and…
TSG-6 protein therapeutics for inflammatory and degenerative disease
Link Biologics is a preclinical-stage biotechnology company developing protein therapeutics based on TSG-6, an endogenous human protein with anti-inflammatory and tissue-protective properties. Spun out from the University of Manchester in 2021, the company is advancing its lead asset, Link_TSG6, across programmes in…
RNA therapeutics targeting cellular senescence and age-related disease
Senisca is a preclinical-stage biotechnology company developing oligonucleotide and small molecule therapeutics that reverse cellular senescence by restoring RNA splicing factor activity. Its platform targets the molecular mechanisms of cellular ageing and has broad applicability across multiple age-related diseases.…
Human iPSC-derived disease models and drug discovery services
Axol Bioscience is a biotechnology company supplying human induced pluripotent stem cell-derived cells and research services for disease modelling and drug discovery. Its portfolio includes neurons, cardiomyocytes, retinal organoids, retinal pigment epithelium and skin cell models, alongside culture media and custom…
AI-enabled biologics discovery and therapeutic development
Divergence Labs develops new medicines by combining molecular engineering, machine learning and high-throughput biological experimentation. Its Cambridge research team integrates antibody and biologics discovery, cell engineering and automated screening to identify and optimise therapeutic candidates. Proprietary…
Dual-pathway AAV gene therapies for retinal degeneration
Ikarovec is a biotechnology company developing dual-pathway adeno-associated virus gene therapies for retinal diseases. Its lead candidate combines complementary mechanisms targeting complement activity, inflammation and retinal cell protection in geographic atrophy. Additional programmes target wet and intermediate…
AI clinical decision support for macular and retinal disease
Macusoft is a London-based health technology company developing AI-powered software to support clinical decision-making in ophthalmology. Its platform assists with diagnosis, triage, and treatment recommendations for macular diseases, diabetic retinopathy, and related retinal conditions, drawing on imaging data and…
Long-acting eye-drop matrix technology for chronic ocular surface disease
Healome Therapeutics is a University of Birmingham spin-out developing a proprietary eye-drop matrix technology that improves drug retention, lubrication and healing on the eye surface. Unlike conventional eye drops, which clear within minutes and often require dosing many times a day, Healome's platform behaves like…
Phase 3 urcosimod therapy for neuropathic corneal pain
OKYO Pharma is a clinical-stage biopharmaceutical company developing topical therapies for neuropathic corneal pain and other ocular surface conditions. Its lead candidate, urcosimod (formerly OK-101), is a chemerin receptor agonist designed to modulate inflammation and corneal pain signalling. Phase 2a testing…
Nanotechnology drug delivery platform for precision medicines
Nanomerics is a UK speciality pharmaceutical company developing precision medicines using its proprietary technology, a polymer nanotechnology platform that improves the bioavailability and targeting of water-insoluble drugs and peptides. The technology enables delivery via nasal, ocular, oral, and blood-brain barrier…
In vivo cell reprogramming therapies for degenerative disease
Mogrify is a biotechnology company developing a novel class of in vivo reprogramming therapies for degenerative diseases. Its proprietary platforms use large-scale transcriptomic and epigenomic network data to predict the transcription factors required to convert mature human cells directly into target therapeutic…
Approved presbyopia eye drops and investigational retinal therapies
Tenpoint Therapeutics is an ophthalmic biopharmaceutical company developing medicines and regenerative cell therapies for age-related vision disorders. Its dual-agent carbachol/brimonidine eye drops received US FDA approval for presbyopia in January 2026 and became commercially available in March. A UK regulatory…
Confocal ophthalmoscope for preclinical retinal imaging in small animals
Vox Imaging Technology is a UK-based developer of laboratory imaging instruments for preclinical eye research. The company's benchtop confocal Scanning Laser Ophthalmoscope is designed for retinal imaging in small animals, built to overcome limitations of existing research instruments identified through consultation…
Gene therapy company targeting inherited and degenerative diseases
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company developing AAV-based gene therapies for inherited retinal diseases, neurodegenerative conditions, and salivary gland disorders. The company operates end-to-end capabilities spanning viral vector design, GMP manufacturing, and clinical…
Amniotic membrane biotherapies for ocular surface repair and regeneration
NuVision Biotherapies is a regenerative medicine company developing tissue-based biotherapies for ocular surface disease and trauma. Its proprietary processing technology manufactures dry-preserved human amniotic membrane grafts that retain the membrane's natural barrier and healing properties whilst enabling ambient…
AAV gene therapy company targeting inherited and common retinal diseases
Beacon Therapeutics is a clinical-stage UK biopharma company developing adeno-associated virus (AAV) gene therapies for retinal diseases causing blindness. Its lead programme, laru-zova (AGTC-501), is in Phase II/III clinical trials for X-linked retinitis pigmentosa. The pipeline also includes preclinical programmes…
AI-powered retinal biomarker platform for early detection of eye and brain disease
Novai is a biotechnology company commercialising DARC (Detection of Apoptosing Retinal Cells), a retinal biomarker platform combining a fluorescent biologic with an AI image analysis algorithm to detect single-cell apoptosis in the retina in vivo. FDA and MHRA approved as an exploratory biomarker, DARC enables early…